UPENDS
28.12.2022 10:56:41 CET | Business Wire | Press release
UPENDS, an e-cigarette brand that prioritizes users’ experience and aims to become the favorite brand for vapers, has recently released its brand new next-gen mesh coil technology and UpBAR GT, the world’s first car concept disposable vape equipped with the next-gen mesh coil.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221227005002/en/
(Photo: Business Wire)
What Does the Next-gen Mesh Coil Mean to the Vape Market?
With the surge of the disposable vape market, countless manufacturers and brands influx into this track, pushing technology innovation quickly. Mesh coil, the key tech of disposable vapes, becomes the essential of tech innovation, which profoundly influences performance like flavor reproduction and puffs. It is obvious that products with stronger next-gen mesh coils will be more competitive in the market.
Next-gen Mesh Coil Comes with Significant Improvements in Performance.
Since the release of its “Mesh Coil is the Future” brand proposition, UPENDS has been dedicated to the innovation of mesh coil technology and has made many breakthroughs. After lab tests and adjustments, UPENDS next-gen mesh coil has been invented successfully. “Compared with traditional mesh coils, its flavor reproduction increased by 38%, puffs increased by 33% and energy efficiency increased by 36% with the same e-liquid capacity”, said Doctor WU, the Chief Product Officer of UPENDS. “We are so excited to release the next-gen mesh coil, and we believe that our customers will be satisfied with the strong performance and longevity it brings.”
UPENDS Makes A Comprehensive Breakthrough in Mesh Coil Technology.
Not only optimizing the coil, UPENDS has also upgraded technologies of the whole cotton coil platform for better performance and quality control. It features a V-shaped air inlet design that can accelerate aerosol delivery, decrease condensate and provide stronger smoke, compared with normal straight channels. Meanwhile, there’s literally no possibility of burnt tastes and oil leakage thanks to its industry-first Tesla value, unique separate air exchange and e-liquid supply channels and multi-layer seal leakage-proof. In addition, it adopts fully-automated manufacturing process technology, aiming to guarantee both production efficiency and stable high quality.
UpBAR GT with Next-gen Mesh Coil is Coming in January 2023.
So what does the next-gen mesh coil bring to UPENDS? UpBAR GT, the first disposable vape equipped with this technology will be the answer. As the “World’s First Car Concept Disposable Vape”, UpBAR GT seeks inspiration from sports cars and stands out from the crowd with its streamlined design and V-shaped grille decorations. GT is the abbreviation of Grand Touring, a type of car designed for high speed and long-distance driving, which also implies the features such as high quality, stability, security and more of UpBAR GT. In addition, there is an eco-friendly version using recycled materials.
About UPENDS
Founded in 2019, UPENDS is an e-cigarette brand dedicated to the field of Electronic Nicotine Delivery Systems. The good reputation of UPENDS as a leading e-cigarette brand in Europe attributes to its excellent manufacturing technology and quality, simple design, and cost-effective features. Currently, UPENDS is expanding its global development. UPENDS persistent pursuit is to prioritize users’ experience and to be Vaper's favorite. For more information, please visit www.upends.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221227005002/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Duco Launches the First Agentic Operations Platform for Financial Services27.5.2026 09:20:00 CEST | Press release
Duco, today launched the first agentic Operations platform for financial services. Built on the engine that already processes 20 billion transactions every month for more than 200 clients, including seven of the top 20 banks and ten of the top 20 asset managers, the platform brings together everything firms need to run post-trade Operations alongside autonomous agents, safely and at scale. The launch establishes a breakthrough the industry has been waiting for. A tool surface, purpose-built for agents. Duco has unbundled its platform into a new alternative agent layer that reconfigures its platform into hundreds of discrete capabilities servicing post trade. Model Context Protocol (MCP) gives capabilities covering reconciliation, data preparation, data access, audit trails, exception management, document creation and more. For the first time, agents have a verified, deterministic toolset built specifically for post-trade. Agents do not replace matching, rules or audit; they use them. P
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release
STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release
Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom